- Clarity Pharmaceuticals (ASX:CU6) images 50 patients with Cu-SAR-Bombesin in its United States-based diagnostic trial, SABRE
- The trial is a multi-centre, single-arm, non-randomised, open-label trial investigating the safety and tolerability of the drug coupled with its potential to detect cancer recurrence
- Participants are currently in phase two, where PET imaging is being used to visualise a PSMA-negative biochemical recurrence (BCR) following drug therapy
- CU6 Executive Chairman Dr Alan Taylor says SAR-Bombesin already results in management improvements of prostate cancer for patients with PSMA-negative or low PSMA-expressing lesions
- CU6 shares are down almost half a per cent, trading at $1.13 at 11:35 am AEDT
Clinical-stage radiopharma company Clarity Pharmaceuticals (ASX:CU6) has imaged 50 patients with Cu-SAR-Bombesin in its United States-based diagnostic trial, SABRE.
The trial is a multi-centre, single-arm, non-randomised, open-label trial of Cu-labelled SAR-Bombesin to investigate the safety and tolerability of the drug coupled with its potential to detect recurrence of prostate cancer.
Participants are currently in phase two, where positron emission tomography (PET) imaging is being used to visualise a PSMA-negative biochemical recurrence (BCR) following drug therapy.
“SAR-Bombesin has already resulted in improvements to the management of prostate cancer for patients with PSMA-negative or low PSMA expressing lesions through our clinical program,” CU6 Executive Chair Dr Alan Taylor said.
“We believe this product has immense potential, both as a theranostic and as a stand-alone diagnostic, as it targets GRPr, which is present in a number of cancers, potentially broadening its use beyond PSMA-negative prostate cancer.”
CU6 shares were down almost half a per cent, trading at $1.13 at 11:35 am AEDT.